{"id":9955,"date":"2018-10-29T15:00:45","date_gmt":"2018-10-29T14:00:45","guid":{"rendered":"https:\/\/asscat-hepatitis.org\/?p=9955"},"modified":"2018-10-29T08:54:48","modified_gmt":"2018-10-29T07:54:48","slug":"quines-son-les-barreres-pel-tractament-de-lhepatitis-c-a-les-presons","status":"publish","type":"post","link":"https:\/\/asscat-hepatitis.org\/ca\/quines-son-les-barreres-pel-tractament-de-lhepatitis-c-a-les-presons\/","title":{"rendered":"Quines s\u00f3n les barreres pel tractament de l\u2019hepatitis C a les presons?"},"content":{"rendered":"<p>[et_pb_section bb_built=&#8221;1&#8243; disabled_on=&#8221;off|off|off&#8221; _builder_version=&#8221;3.0.106&#8243; custom_margin=&#8221;|||&#8221; custom_padding=&#8221;0px||0px|&#8221; next_background_color=&#8221;#000000&#8243;][et_pb_row custom_padding=&#8221;0px||0px|&#8221; _builder_version=&#8221;3.0.106&#8243; background_size=&#8221;initial&#8221; background_position=&#8221;top_left&#8221; background_repeat=&#8221;repeat&#8221;][et_pb_column type=&#8221;4_4&#8243;][et_pb_post_title author=&#8221;off&#8221; date_format=&#8221;d\/m\/Y&#8221; comments=&#8221;off&#8221; featured_placement=&#8221;background&#8221; text_background=&#8221;on&#8221; text_bg_color=&#8221;#ffffff&#8221; module_class=&#8221;ac-post-title-section-0&#8243; _builder_version=&#8221;3.0.106&#8243; title_font=&#8221;Montserrat|600|||||||&#8221; title_text_color=&#8221;#2d2d2d&#8221; title_letter_spacing=&#8221;-1px&#8221; title_line_height=&#8221;1.2em&#8221; meta_font=&#8221;Open Sans||||||||&#8221; meta_text_color=&#8221;rgba(45,45,45,0.5)&#8221; text_orientation=&#8221;center&#8221; custom_margin=&#8221;|||&#8221; custom_padding=&#8221;|20px|20px|20px&#8221; title_text_align=&#8221;center&#8221; meta_font_size=&#8221;13px&#8221; meta_text_align=&#8221;center&#8221;]<\/p>\n<p>&nbsp;<\/p>\n<p>[\/et_pb_post_title][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section bb_built=&#8221;1&#8243; specialty=&#8221;on&#8221; _builder_version=&#8221;3.0.106&#8243; custom_padding=&#8221;0px|||&#8221; prev_background_color=&#8221;#000000&#8243; next_background_color=&#8221;#000000&#8243;][et_pb_column type=&#8221;2_3&#8243; specialty_columns=&#8221;2&#8243;][et_pb_row_inner admin_label=&#8221;Fila&#8221; _builder_version=&#8221;3.0.106&#8243;][et_pb_column_inner type=&#8221;4_4&#8243; saved_specialty_column_type=&#8221;2_3&#8243;][et_pb_text admin_label=&#8221;Contenido Entrada 1&#8243; ul_type=&#8221;square&#8221; module_class=&#8221;ac-posts-content&#8221; _builder_version=&#8221;3.0.106&#8243; text_orientation=&#8221;justified&#8221; background_layout=&#8221;light&#8221;]<\/p>\n<h3>La manca de privacitat, la manca de suport entre iguals i la manca de reducci\u00f3 de danys es perceben com les majors barreres per millorar l\u2019acceptaci\u00f3 del tractament antiviral d\u2019acci\u00f3 directa per a l\u2019hepatitis C entre els presos, segons un estudi qualitatiu entre els presos a Austr\u00e0lia.<\/h3>\n<p>Els descobriments, publicats al <em>Journal of Viral Hepatitis<\/em>, subratllen la necessitat de missatges de les autoritats de la pres\u00f3 que emfatitzen l\u2019oportunitat de tractament, diuen els autors de l\u2019estudi, que estan associats amb l\u2019estudi STOP-C de l\u2019eliminaci\u00f3 de l\u2019hepatitis C a les presons de l\u2019estat de Nova Gales del Sud.<\/p>\n<p>L\u2019hepatitis C \u00e9s altament prevalent entre els presos, ja que moltes persones empresonades tenen un historial d\u2019\u00fas de drogues injectables. L\u2019enquesta m\u00e9s recent sobre la prevalen\u00e7a del virus de l\u2019hepatitis C (VHC) entre els presos a Austr\u00e0lia va trobar que el 22% va donar positiu pel VHC i el 58% va informar haver-se injectat drogues en algun moment en el passat. La prevalen\u00e7a del VHC entre les persones que s\u2019injecten drogues a les presons d\u2019Austr\u00e0lia pot arribar al 60%.<\/p>\n<p>A m\u00e9s de beneficiar al pres individual, augmentar l\u2019acceptaci\u00f3 del tractament antiviral d\u2019acci\u00f3 directa tamb\u00e9 tindria beneficis preventius m\u00e9s amplis, a l\u2019eliminar l\u2019hepatitis C en persones que s\u2019injecten drogues tant dins de xarxes tancades en les quals l\u2019intercanvi d\u2019equips d\u2019injecci\u00f3 es realitza dins de la pres\u00f3 i tamb\u00e9 en el llan\u00e7ament. L\u2019<a href=\"https:\/\/kirby.unsw.edu.au\/project\/stop-c\">estudi STOP-C<\/a> est\u00e0 examinant si la r\u00e0pida ampliaci\u00f3 del tractament antiviral d\u2019acci\u00f3 directa a les presons pot reduir la incid\u00e8ncia del VHC entre els presos.<\/p>\n<p>Si b\u00e9 els reclusos han de tenir igual acc\u00e9s a l\u2019atenci\u00f3 m\u00e8dica en virtut dels acords internacionals de drets humans, l\u2019acceptaci\u00f3 del tractament de l\u2019hepatitis C entre els reclusos \u00e9s baixa fins i tot quan es proporciona.<\/p>\n<p>Per explorar les barreres per iniciar el tractament antiviral d\u2019acci\u00f3 directa a les presons, els investigadors van entrevistar a 32 presoners en quatre centres penitenciaris a Nova Gales del Sud.<\/p>\n<p>Tots els participants tenien un historial d\u2019\u00fas de drogues injectables, la meitat d\u2019ells tenien infecci\u00f3 cr\u00f2nica per VHC, tres havien eliminat la infecci\u00f3 pr\u00e8via de forma espont\u00e0nia i la resta s\u2019havia curat de l\u2019hepatitis C o estaven esperant els resultats de les proves virol\u00f2giques posteriors al tractament. Catorze estaven rebent ter\u00e0pia de substituci\u00f3 d\u2019opioides en el moment de l\u2019entrevista.<\/p>\n<p>Els participants van descobrir que les cl\u00edniques de la pres\u00f3 podrien proporcionar una atenci\u00f3 m\u00e8dica convenient en el lloc que super\u00e9s les barreres de dist\u00e0ncia i el transport experimentat fora de la pres\u00f3.<\/p>\n<p>Alguns participants tamb\u00e9 van pensar que la pres\u00f3 oferia l\u2019oportunitat de lidiar amb problemes de salut que podrien posar-se de banda en el m\u00f3n exterior degut a altres pressions. Els problemes amb l\u2019\u00fas de drogues i la vivenda van ser citats com a exemples.<\/p>\n<p>Per\u00f2 els participants sovint van veure estar a pres\u00f3 com una gran barrera estructural per curar-se, degut a la manca d\u2019acc\u00e9s a agulles i xeringues netes.<\/p>\n<p>Alguns van pensar que el millor moment per completar un curs de tractament podria ser just abans de sortir de la pres\u00f3, ja que aix\u00f2 minimitzaria el risc de reinfectar-se degut a la manca d\u2019agulles i xeringues netes.<\/p>\n<p>La confidencialitat tamb\u00e9 va ser una gran preocupaci\u00f3 pels participants que usaven cl\u00edniques de salut a les presons. Ser identificat com tenir VHC podria portar a l\u2019exclusi\u00f3 de les xarxes d\u2019injecci\u00f3 a la pres\u00f3 o altres conseq\u00fc\u00e8ncies socials indesitjables. Les preocupacions sobre la confidencialitat i la pressi\u00f3 per revelar els motius de les visites a la cl\u00ednica de la pres\u00f3 tamb\u00e9 s\u2019han citat en investigacions anteriors com barreres per a les proves de detecci\u00f3 del VHC a les presons.<\/p>\n<p>La manca de suport de familiars i amics tamb\u00e9 es va citar com una barrera: <em>\u201cvosaltres sabeu, veritables amics\u201d<\/em>, com ho va expressar un pres que havia passar per un tractament infructu\u00f3s.<\/p>\n<p>Els investigadors suggereixen que els serveis de salut de la pres\u00f3 que busquen encoratjar el tractament han d\u2019emfatitzar els seg\u00fcents missatges als reclusos amb VHC:<\/p>\n<ul>\n<li>Facilitat d\u2019acc\u00e9s al tractament a la pres\u00f3.<\/li>\n<li>L\u2019acc\u00e9s al tractament contra el VHC a la pres\u00f3 \u00e9s una oportunitat de superaci\u00f3 personal abans del llan\u00e7ament, un \u201cnou inici\u201d.<\/li>\n<li>El tractament \u00e9s gratu\u00eft.<\/li>\n<\/ul>\n<p>Les presons tamb\u00e9 han de centrar-se en portar les xarxes d\u2019injecci\u00f3 en tractament en lloc de penalitzar la injecci\u00f3. El tractament de xarxes d\u2019injecci\u00f3 completes al mateix temps tamb\u00e9 reduiria el risc de reinfecci\u00f3 en abs\u00e8ncia de programes d\u2019agulles i xeringues a les presons.<\/p>\n<p>&nbsp;<\/p>\n<p>Font: <a href=\"http:\/\/www.infohep.org\/What-are-the-barriers-to-hepatitis-C-treatment-in-prisons\/page\/3351232\/\">infohep.org<\/a><\/p>\n<p>Refer\u00e8ncia: Lafferty L <em>et al.<\/em> Understanding facilitators and barriers of direct-acting antiviral therapy for hepatitis C virus infection in prison. J Viral Hepat, advance online publication August 2018.<\/p>\n<p>Not\u00edcia tradu\u00efda per l\u2019ASSCAT<\/p>\n<p>[\/et_pb_text][\/et_pb_column_inner][\/et_pb_row_inner][et_pb_row_inner admin_label=&#8221;Fila&#8221; custom_padding=&#8221;0px|||&#8221; _builder_version=&#8221;3.0.105&#8243; custom_margin=&#8221;|||&#8221;][et_pb_column_inner type=&#8221;4_4&#8243; saved_specialty_column_type=&#8221;2_3&#8243;][et_pb_post_title admin_label=&#8221;Metadatos &#8211; Fecha \u00daltima actualizaci\u00f3n&#8221; title=&#8221;off&#8221; author=&#8221;off&#8221; date_format=&#8221;d\/m\/Y&#8221; categories=&#8221;off&#8221; comments=&#8221;off&#8221; featured_image=&#8221;off&#8221; _builder_version=&#8221;3.0.106&#8243; title_text_align=&#8221;left&#8221; meta_font=&#8221;Open Sans||||||||&#8221; meta_text_align=&#8221;left&#8221; meta_font_size=&#8221;13px&#8221; meta_text_color=&#8221;#0082ca&#8221; border_width_top=&#8221;1px&#8221; border_color_top=&#8221;#cccccc&#8221; custom_margin=&#8221;50px|||&#8221; custom_padding=&#8221;10px|||&#8221; custom_css_before=&#8221;content:%22\u00daltima actualizaci\u00f3n:%22;&#8221; global_module=&#8221;3449&#8243; saved_tabs=&#8221;all&#8221;]<\/p>\n<p>&nbsp;<\/p>\n<p>[\/et_pb_post_title][\/et_pb_column_inner][\/et_pb_row_inner][\/et_pb_column][et_pb_column type=&#8221;1_3&#8243;][et_pb_sidebar orientation=&#8221;right&#8221; area=&#8221;et_pb_widget_area_8&#8243; module_class=&#8221;ac-posts-sidebar&#8221; _builder_version=&#8221;3.0.106&#8243; global_module=&#8221;3198&#8243; saved_tabs=&#8221;all&#8221;]<\/p>\n<p>&nbsp;<\/p>\n<p>[\/et_pb_sidebar][\/et_pb_column][\/et_pb_section][et_pb_section bb_built=&#8221;1&#8243; _builder_version=&#8221;3.0.106&#8243; custom_padding=&#8221;||0px|&#8221; prev_background_color=&#8221;#000000&#8243; module_class=&#8221;ac-post-section-share-rrss&#8221;][et_pb_row custom_padding=&#8221;||0px|&#8221; custom_margin=&#8221;|||&#8221; _builder_version=&#8221;3.0.105&#8243; background_size=&#8221;initial&#8221; background_position=&#8221;top_left&#8221; background_repeat=&#8221;repeat&#8221;][et_pb_column type=&#8221;4_4&#8243;][et_pb_divider color=&#8221;#e20611&#8243; show_divider=&#8221;on&#8221; divider_style=&#8221;ridge&#8221; _builder_version=&#8221;3.0.106&#8243; \/][et_pb_text _builder_version=&#8221;3.0.106&#8243; text_font=&#8221;Montserrat||||||||&#8221; text_text_color=&#8221;#e20611&#8243; text_orientation=&#8221;center&#8221; custom_margin=&#8221;||0px|&#8221; custom_padding=&#8221;|||&#8221; background_layout=&#8221;light&#8221; disabled=&#8221;on&#8221;]<\/p>\n<h5>Desde aqu\u00ed puedes compartir esta publicaci\u00f3n. \u00a1Gracias!<\/h5>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>\n<!-- Begin Yuzo --><div class='yuzo_related_post style-1'  data-version='5.12.77'><!-- without result --><div class='yuzo_clearfixed yuzo__title yuzo__title'><h3>Related Post<\/h3><\/div>\n\t\t\t\t\t\t  <div class=\"relatedthumb \" style=\"width:125px;float:left;overflow:hidden;\">  \n\t\t\t\t\t\t\t  \n\t\t\t\t\t\t\t  <a  href=\"https:\/\/asscat-hepatitis.org\/ca\/quan-es-el-moment-adequat-per-tractar-lhepatitis-c-en-persones-amb-cancer-de-fetge\/\"  >\n\t\t\t\t\t\t\t\t\t  <div class=\"yuzo-img-wrap \" style=\"width: 125px;height:90px;\">\n\t\t\t\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t<div class=\"yuzo-img\" style=\"background:url('https:\/\/asscat-hepatitis.org\/wp-content\/uploads\/cancer-higado-6-150x150.jpg') 50% 50% no-repeat;width: 125px;height:90px;margin-bottom: 5px;background-size: cover; \"><\/div>\n\t\t\t\t\t\t\t\t\t  <\/div>\n\t\t\t\t\t\t\t\t\t  \n\t\t\t\t\t\t\t\t   <span class=\"yuzo__text--title\" style=\"font-size:13px;\">Quan \u00e9s el moment adequat per tractar l\u2019hepatitis ...<\/span>\n\t\t\t\t\t\t\t  \n\t\t\t\t\t\t\t  \n\t\t\t\t\t\t\t  <\/a>\n\n\t\t\t\t\t\t  <\/div>\n\t\t\t\t\t\t  <div class=\"relatedthumb \" style=\"width:125px;float:left;overflow:hidden;\">  \n\t\t\t\t\t\t\t  \n\t\t\t\t\t\t\t  <a  href=\"https:\/\/asscat-hepatitis.org\/ca\/reobertura-segura-quin-equip-de-proteccio-personal-usar-en-latencio-primaria\/\"  >\n\t\t\t\t\t\t\t\t\t  <div class=\"yuzo-img-wrap \" style=\"width: 125px;height:90px;\">\n\t\t\t\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t<div class=\"yuzo-img\" style=\"background:url('https:\/\/asscat-hepatitis.org\/wp-content\/uploads\/atencion-primaria-150x150.jpeg') 50% 50% no-repeat;width: 125px;height:90px;margin-bottom: 5px;background-size: cover; \"><\/div>\n\t\t\t\t\t\t\t\t\t  <\/div>\n\t\t\t\t\t\t\t\t\t  \n\t\t\t\t\t\t\t\t   <span class=\"yuzo__text--title\" style=\"font-size:13px;\">Reobertura segura: quin equip de protecci\u00f3 persona...<\/span>\n\t\t\t\t\t\t\t  \n\t\t\t\t\t\t\t  \n\t\t\t\t\t\t\t  <\/a>\n\n\t\t\t\t\t\t  <\/div>\n\t\t\t\t\t\t  <div class=\"relatedthumb \" style=\"width:125px;float:left;overflow:hidden;\">  \n\t\t\t\t\t\t\t  \n\t\t\t\t\t\t\t  <a  href=\"https:\/\/asscat-hepatitis.org\/ca\/recomanacions-pel-tractament-de-lhepatitis-c-2018-easl\/\"  >\n\t\t\t\t\t\t\t\t\t  <div class=\"yuzo-img-wrap \" style=\"width: 125px;height:90px;\">\n\t\t\t\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t<div class=\"yuzo-img\" style=\"background:url('https:\/\/asscat-hepatitis.org\/wp-content\/uploads\/CPG_Treatment-of-Hepatitis-C-2018-1-150x150.jpg') 50% 50% no-repeat;width: 125px;height:90px;margin-bottom: 5px;background-size: cover; \"><\/div>\n\t\t\t\t\t\t\t\t\t  <\/div>\n\t\t\t\t\t\t\t\t\t  \n\t\t\t\t\t\t\t\t   <span class=\"yuzo__text--title\" style=\"font-size:13px;\">Recomanacions pel tractament de l\u2019hepatitis ...<\/span>\n\t\t\t\t\t\t\t  \n\t\t\t\t\t\t\t  \n\t\t\t\t\t\t\t  <\/a>\n\n\t\t\t\t\t\t  <\/div>\n\t\t\t\t\t\t  <div class=\"relatedthumb \" style=\"width:125px;float:left;overflow:hidden;\">  \n\t\t\t\t\t\t\t  \n\t\t\t\t\t\t\t  <a  href=\"https:\/\/asscat-hepatitis.org\/ca\/fetge-gras-no-alcoholic-la-seva-prevalenca-augmenta-al-mon\/\"  >\n\t\t\t\t\t\t\t\t\t  <div class=\"yuzo-img-wrap \" style=\"width: 125px;height:90px;\">\n\t\t\t\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t<div class=\"yuzo-img\" style=\"background:url('https:\/\/asscat-hepatitis.org\/wp-content\/uploads\/higado-graso-27-150x150.jpg') 50% 50% no-repeat;width: 125px;height:90px;margin-bottom: 5px;background-size: cover; \"><\/div>\n\t\t\t\t\t\t\t\t\t  <\/div>\n\t\t\t\t\t\t\t\t\t  \n\t\t\t\t\t\t\t\t   <span class=\"yuzo__text--title\" style=\"font-size:13px;\">Fetge gras no alcoh\u00f2lic: la seva prevalen\u00e7a augmen...<\/span>\n\t\t\t\t\t\t\t  \n\t\t\t\t\t\t\t  \n\t\t\t\t\t\t\t  <\/a>\n\n\t\t\t\t\t\t  <\/div>\n<\/div> <style>\n\t\t\t\t\t\t\t\t.yuzo_related_post img{width:120px !important; height:110px !important;}\n\t\t\t\t\t\t\t\t.yuzo_related_post .relatedthumb{line-height:15px;background: !important;color:!important;}\n\t\t\t\t\t\t\t\t.yuzo_related_post .relatedthumb:hover{background:#fcfcf4 !important; -webkit-transition: background 0.2s linear; -moz-transition: background 0.2s linear; -o-transition: background 0.2s linear; transition: background 0.2s linear;;color:!important;}\n\t\t\t\t\t\t\t\t.yuzo_related_post .relatedthumb a{color:!important;}\n\t\t\t\t\t\t\t\t.yuzo_related_post .relatedthumb a:hover{ color:}!important;}\n\t\t\t\t\t\t\t\t.yuzo_related_post .relatedthumb:hover a{ color:!important;}\n\t\t\t\t\t\t\t\t.yuzo_related_post .yuzo_text {color:!important;}\n\t\t\t\t\t\t\t\t.yuzo_related_post .relatedthumb:hover .yuzo_text {color:!important;}\n\t\t\t\t\t\t\t\t.yuzo_related_post .relatedthumb{  margin: 0px  0px  0px  0px;   padding: 5px  5px  5px  5px;  }\n\t\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\t<\/style> <script>\n\t\t\t\t\t\t  jQuery(document).ready(function( $ ){\n\t\t\t\t\t\t\t\/\/jQuery('.yuzo_related_post').equalizer({ overflow : 'relatedthumb' });\n\t\t\t\t\t\t\tjQuery('.yuzo_related_post .yuzo_wraps').equalizer({ columns : '> div' });\n\t\t\t\t\t\t   })\n\t\t\t\t\t\t  <\/script> <!-- End Yuzo :) -->","protected":false},"excerpt":{"rendered":"<p>La manca de privacitat, la manca de suport entre iguals i la manca de reducci\u00f3 de danys es perceben com les majors barreres per millorar l\u2019acceptaci\u00f3 del tractament AAD per a l\u2019hepatitis C entre els presos, segons un estudi qualitatiu entre els presos a Austr\u00e0lia.<\/p>\n","protected":false},"author":9,"featured_media":9957,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_crdt_document":"","footnotes":""},"categories":[567,491],"tags":[995,496,2203,1169,498,2012,915,1126,1297],"class_list":["post-9955","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-articulos-ca","category-noticias-de-prensa-ca","tag-aad","tag-australia-ca","tag-barreres-eliminacio","tag-estudi","tag-hepatitis-c-ca","tag-journal-of-viral-hepatitis","tag-premsa","tag-presons","tag-reduccio-de-danys"],"_links":{"self":[{"href":"https:\/\/asscat-hepatitis.org\/ca\/wp-json\/wp\/v2\/posts\/9955","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/asscat-hepatitis.org\/ca\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/asscat-hepatitis.org\/ca\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/asscat-hepatitis.org\/ca\/wp-json\/wp\/v2\/users\/9"}],"replies":[{"embeddable":true,"href":"https:\/\/asscat-hepatitis.org\/ca\/wp-json\/wp\/v2\/comments?post=9955"}],"version-history":[{"count":0,"href":"https:\/\/asscat-hepatitis.org\/ca\/wp-json\/wp\/v2\/posts\/9955\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/asscat-hepatitis.org\/ca\/wp-json\/wp\/v2\/media\/9957"}],"wp:attachment":[{"href":"https:\/\/asscat-hepatitis.org\/ca\/wp-json\/wp\/v2\/media?parent=9955"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/asscat-hepatitis.org\/ca\/wp-json\/wp\/v2\/categories?post=9955"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/asscat-hepatitis.org\/ca\/wp-json\/wp\/v2\/tags?post=9955"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}